丙型肝炎病毒相关慢性肝病患者肝脏中干扰素-α/β受体蛋白的表达

Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease.

作者信息

Meng Xiang-Wei, Chi Bao-Rong, Chen Li-Gang, Zhang Ling-Ling, Zhuang Yan, Huang Hai-Yan, Sun Xun

机构信息

Department of Gastroenterology, the First Affiliated Hospital, Jilin University, Changchun 130021, Jilin Province, China.

出版信息

World J Gastroenterol. 2005 Jul 7;11(25):3962-5. doi: 10.3748/wjg.v11.i25.3962.

DOI:10.3748/wjg.v11.i25.3962

PMID:15991303

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4504906/

Abstract

AIM

To study the expression of interferon-alpha/beta (IFN-alpha/beta) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance.

METHODS

A total of 181 patients with HCV-related chronic liver disease included 56 with HCV-related liver cirrhosis (LC) and 125 with chronic hepatitis C (CHC). CHC patients were treated with five megaunits of interferon-?1b six times weekly for the first 2 weeks and then every other day for 22 wk. The patients were divided into interferon (IFN) treatment-responsive and non-responsive groups, but 36 patients lost follow-up shortly after receiving the treatment. The expression of IFN-alpha/beta receptor (IFN-alpha/betaR) protein in liver of all patients was determined with immunofluorescence.

RESULTS

In liver of patients with HCV-related chronic liver disease, the expression of IFN-alpha/betaR protein in liver cell membrane was stronger than that in cytoplasm and more obvious in the surroundings of portal vein than in the surroundings of central vein. Moreover, it was poorly distributed in hepatic lobules. The weak positive, positive and strong positive expression of IFN-alpha/betaR were 40% (50/125), 28% (35/125), 32% (40/125), respectively in CHC group, and 91.1% (51/56), 5.35% (3/56), and 3.56% (2/56), respectively in LC group. The positive and strong positive rates were higher in CHC group than in LC group (P<0.01). In IFN treatment responsive group, 27.8% (10/36) showed weak positive expression; 72.2% (26/36) showed positive or strong positive expression. In the non-responsive group, 71.7% (38/53) showed weak positive expression; 28.3% (15/53) showed positive or strong positive expression. The expression of IFN-alpha/betaR protein in liver was more obvious in IFN treatment responsive group than in non-responsive group.

CONCLUSION

Expression of IFN-alpha/betaR protein in liver of patients with HCV-related chronic liver disease is likely involved in the response to IFN treatment.

摘要

目的

研究丙型肝炎病毒（HCV）相关慢性肝病患者肝脏中α/β干扰素（IFN-α/β）受体蛋白的表达及其临床意义。

方法

181例HCV相关慢性肝病患者，其中56例为HCV相关肝硬化（LC），125例为慢性丙型肝炎（CHC）。CHC患者在治疗的前2周每周6次给予500万单位的干扰素-β1b，之后每2天1次，共22周。将患者分为干扰素（IFN）治疗反应组和无反应组，但36例患者在接受治疗后不久失访。采用免疫荧光法检测所有患者肝脏中IFN-α/β受体（IFN-α/βR）蛋白的表达。

结果

在HCV相关慢性肝病患者肝脏中，IFN-α/βR蛋白在肝细胞膜上的表达强于细胞质，在门静脉周围比中央静脉周围更明显。此外，其在肝小叶中分布较差。在CHC组中，IFN-α/βR的弱阳性、阳性和强阳性表达分别为40%（50/125）、28%（35/125）、32%（40/125），在LC组中分别为91.1%（51/56）、5.35%（3/56）和3.56%（2/56）。CHC组的阳性和强阳性率高于LC组（P<0.01）。在IFN治疗反应组中，27.8%（10/36）呈弱阳性表达；72.2%（26/36）呈阳性或强阳性表达。在无反应组中，71.7%（38/53）呈弱阳性表达；28.3%（15/53）呈阳性或强阳性表达。IFN治疗反应组肝脏中IFN-α/βR蛋白的表达比无反应组更明显。